
Veracyte (VCYT) Stock Forecast & Price Target
Veracyte (VCYT) Analyst Ratings
Bulls say
Veracyte is a genomic diagnostics company that provides tests for various types of cancer, including prostate, thyroid, breast, and bladder. They have a positive outlook due to potential market growth, successful clinical data for their breast cancer test Prosigna, and plans for international expansion. The company has also exceeded financial expectations and has a strong development pipeline, but there are potential risks to consider.
Bears say
Veracyte is a genomic diagnostics company with a portfolio of tests for prostate, thyroid, breast, and bladder cancers. While the company has shown strong revenue growth in recent years and has potential for continued success with new partnerships, there are concerns about the sustainability of this growth and the company's margin performance. Additionally, its dependency on a small portion of its revenue from the Prosigna test and potential competition in the future could impact its financials.
This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares